knowledge -WSS

knowledge

author：explore 2025-08-12 11:29:54 - browse：51654

Steven Pearson — ICER President Steven D. Pearson Craig F. Walker/The Boston Globe

Meetings of the Institute for Clinical and Economic Review don’t usually get one’s heart pumping. But a meeting Thursday at the Massachusetts Institute of Technology may prove to be the exception to that rule.

Patients Rising Now, an advocacy group that says it promotes transparency in health care and that is a fierce opponent of ICER’s, is expected to face off with the self-professed “watchdog of drug pricing” as it reviews three drugs for Duchenne muscular dystrophy.

Dozens of Duchenne patients and their families — many of whom also express concern that ICER’s review could undermine insurers’ already tepid interest in the treatments — are also expected to be in attendance.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： MD Anderson's Padmanee Sharma responds to research credit suit

WSS

NIH study of ME/CFS points to clear biological hallmarks

Surprise medical billing ban raises prices elsewhere

NIH study of ME/CFS points to clear biological hallmarks

NIH study of ME/CFS points to clear biological hallmarks

Weight loss drugs aren’t covered by Obamacare. That may change

New study raises questions about niacin and heart health

leisure time

knowledge

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Medical records are filled with copy

As AI regulations shape up, health tech startups beg for clarity

BioMarin wins approval for gene therapy to treat hemophilia A

Alabama IVF ruling threatens families facing fatal genetic disease

How to save PrEP access — and even expand it

Reporting on presidential health from Reagan to Trump and Biden

Activists slam private health insurers over coverage restrictions

FDA warns medical device makers about rise in fabricated data

focus

NIH study of ME/CFS points to clear biological hallmarks

Obesity drugs seen as possible treatment for liver disease MASH

R1 RCM gets $5.8 billion buyout offer from private equity firm

The Harvard botanist who searched for psychedelics in the Amazon

Hospitals are piloting generative AI tools as regulators play catch

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

leisure time

hotspot

knowledge

hotspot